Replies to post #84921 on Biotech Values

[rkrw]

Its that the company they partnered with was acquired. That's an extra layer of risk that a deal may be voided. Solvay as a mid tier pharma as a partner was less surprising than had someone like abbott jumped in initially. Who can say abbott is ok with this indication splitting or a generic+ product as solvay apparently was? I'm not trying to argue with you, just pointing out it's a risk.